Bradykinin mediated angioedema
Bradykinin mediated angioedema
复制标题
DOI：
10.1016/j.revmed.2009.11.021
复制
发表时间：
2011-04-01
影响因子：
0.9
通讯作者：
Massot, C.
中科院分区：
文献类型：
--
作者：
Bouillet, L.;Boccon-Gibod, I.;Massot, C.
缓激肽血管性水肿（AE）的特征是局部肿胀的急性复发性发作。它们与瘙痒或红斑无关，并且是短暂的（24至72小时），消失无任何后遗症。皮质类固醇没用。皮肤或粘膜（上呼吸道和肠道）可能受到影响。缓激肽AE可能继发于：（1）与Cl抑制剂缺乏相关的AE（遗传性或获得性）;（2）药物诱导的AE（转化酶抑制剂）：(3)III型AE型（雌激素依赖型），无Cl抑制剂缺乏。这些III型AE可能与显著增加因子XII活性的功能获得突变相关。预后取决于喉部发作（在没有具体治疗的情况下，导致25%的死亡）。在严重发作的情况下，可使用艾替班特（缓激肽受体拮抗剂）或Cl抑制剂浓缩物。在频繁发作的情况下，达那唑或氨甲环酸的长期治疗是有效的。(C)2010年法国国家内科医学协会（SNFMI）。由Elsevier Masson SAS出版。All rights reserved.
Bradykinin angioedema (AE) are characterized by acute recurrent episodes of localized swelling. They are not associated with pruritus or erythema, and are short-lived (24 to 72 hours), disappearing without any sequelae. Corticosteroids are useless. Skin or mucous membranes (upper respiratory and intestinal) could be affected. Bradykinin AE can be secondary to: (1) AE associated with Cl inhibitor deficiency (hereditary or acquired); (2) drug-induced AE (converting enzyme inhibitors...): (3) type III AE type (oestrogen dependant) without Cl inhibitor deficiency. These type III AE can be associated with a gain of function mutation that markedly increases factor XII activity. Prognosis depends on the laryngeal attacks (resulting in 25% of death in the absence of specific treatment). In case of severe attacks, icatibant (bradykinin receptor antagonist) or Cl inhibitor concentrate can be used. In case of frequent attacks, long-term therapy with danazol or tranexamic acid is effective. (C) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.